Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Close Follow-Up Versus Adjuvant Chemotherapy in Stage IB-IIA Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07751302Recruiting
- Sponsor
- Xijing Hospital
- Start
- Aug 2026
- Primary completion
- Jan 2036
- Countries
- 1
01
Overview
Randomised, open-label trial of tegafur + gimeracil + oteracil in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Xijing Hospital. Primary endpoint: Disease-Free Survival at 5 years. Started Aug 2026; status: recruiting.
02
Drugs
tegafur + gimeracil + oteracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07751302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07751302.